Austin, Texas—Building on the company’s nearly decade-long track record of developing advanced genomics reports to provide actionable insight into conditions ranging from age-related cognitive decline to autism spectrum disorder, IntellxxDNA is thrilled to launch a new, clinically proven genomics report for anxiety and depression.
Traditional mental health care has often taken a “one-size-fits-all” approach, addressing conditions like anxiety and depression with generalized treatments that primarily target serotonin or GABA levels. While these solutions offer relief to many, they frequently fail, leading to a “trial and error” approach to medication that can make life even more difficult for patients.
With advances in genomics, personalized medicine can increasingly improve on trial and error treatments. IntellxxDNA aims to do just that with the launch of its Spotlight on Anxiety and Depression Report. This cutting-edge genomics report equips healthcare providers with a comprehensive genomic analysis that can shed light on root genetic causes of mental health disorders and provide actionable interventions.
The Anxiety & Depression Report leverages SNPs to help clinicians identify underlying genetic causes of depression and anxiety. Analyzing over 40 carefully selected and clinically relevant single nucleotide polymorphisms (SNPs), the reports shed light on genetic factors tied to key risk elements such as serotonin and norepinephrine levels, along with gene variants influencing cortisol, brain histamine, adrenaline, thyroid metabolism, and other co-factors linked to higher anxiety and depression risks.
Additionally, recognizing the role of nutrition, environment, and inflammation in mental health, IntellxxDNA’s report examines SNPs in these areas as well. The reports provide clinicians with actionable interventions, guiding them in addressing these genetic factors through tailored treatment plans that include medications, supplements, nutrients, and lifestyle changes.
“After years of debilitating anxiety, my daughter is finally going to school regularly, making friends, and joining clubs. Without the IntellxxDNA report, her doctors would never have found the root cause. Six months after starting treatment, we haven’t seen even a trace of her once-paralyzing anxiety. It was incredible when she told me, ‘Dad, it feels so good not to have anxiety anymore,’ ” said Erik, the parent of a patient.
This moving testimonial highlights how the Spotlight on Anxiety and Depression Report uncovers crucial genetic factors that traditional treatments may overlook, offering patients renewed hope and a path to recovery.
A New Era for Psychiatry
The Spotlight on Anxiety and Depression Report sets a new benchmark for psychiatrists and family physicians managing or referring mental health cases. By leveraging advanced genetic data, it enables healthcare providers to deliver personalized care that addresses root genetic factors contributing to depression and anxiety, leading to more effective and lasting outcomes.
“So many of our medications for depression, such as SSRIs, focus solely on serotonin, but mental health is often much more multifactorial. Numerous factors contribute to low serotonin, such as the availability of cofactors. The beauty of the IntellxxDNA Spotlight on Anxiety and Depression Report is that it examines all the different areas affecting serotonin production, uptake, and reuptake, offering a much more sophisticated picture than simply prescribing an SSRI,” said Kirkland Newman, CEO of MindHealth360.
Register here to join Dr. Sharon Hausman-Cohen on November 19 at 7 PM CST for a free webinar discussing the new Spotlight on Anxiety & Depression Report.
About IntellxxDNA™
IntellxxDNA™ is the leader in DNA-targeted precision medicine. By equipping clinicians with deep molecular insights into their patients, we make genomics truly actionable, enabling evidence-based, precision treatments. Our mission is to advance quality of life for all individuals through innovative, personalized approaches.